Giulia Pasello

Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging

Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Pro-senescence therapy for cancer treatment

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Dermatologic Reactions to Immune Checkpoint Inhibitors

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Cellular senescence in ageing: from mechanisms to therapeutic opportunities

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

Targeting apoptosis in cancer therapy

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Oxidative Stress in Cancer

ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age‐Related Diseases

How the ageing microenvironment influences tumour progression

The role of senescent cells in ageing

<p>Reactive Oxygen Species: Drivers of Physiological and Pathological Processes</p>

The functions and regulation of the PTEN tumour suppressor

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cellular senescence: from physiology to pathology

Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage

Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Precise Modulation of CO₂ Sorption in Ti₈Ce₂–Oxo Clusters: Elucidating Lewis Acidity of the Ce Metal Sites and Structural Flexibility

Antioxidant Therapy in Cancer: Rationale and Progress

Metabolic rewiring and redox alterations in malignant pleural mesothelioma

Second- and Third-line Treatment in Advanced Non-small-cell Lung Cancer

Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment

Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Second and third line treatment in advanced non-small cell lung cancer.

Effects of Sulfonylureas on Tumor Growth: A Review of the Literature